AlphaYou
Overview
Key stats
Fundamentals Sep 12- Open
- $27.69
- 52-wk high
- $29.21
- High
- $27.75
- 52-wk low
- $22.03
- Low
- $27.40
- Prev close
- $27.65
- Mkt cap
- $157.60B
- P/E
- 36.4x
- Volume
- 28.81M
- Fwd P/E
- 9.5x
- Beta
- 0.30
- Div yield
- 6.19%
- P/S
- 2.5x
- P/B
- 1.9x
- Profit margin
- +6.8%
- Op margin
- +27.9%
- ROE
- +5.0%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position, insiders have been net selling, and 1 fin-fluencer is discussing it.
What funds are doing
Earnings
Earnings came in 13.2% above what analysts expected.
Earnings per share
$0.68 expected
Revenue
$14.39B expected
GAAP EPS was -$0.04 and adjusted EPS was $0.77. The adjusted figure is comparable to consensus.
FY2026 guidance
$60.50B to $62.50B
No comparable estimate
Reports Nov 3, 2026, in 51 days
EPS expected
$0.59 to $0.94
Revenue expected
16 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $16.65B | $17.56B | $14.45B | $15.03B |
| Cost of what it sold | $4.17B | $5.27B | $4.73B | $4.09B |
| Gross profit | $12.48B | $12.29B | $9.72B | $10.94B |
| What it spent | ||||
| Research and development | $3.94B | $3.42B | $2.63B | $2.81B |
| Sales and admin | $3.19B | $4.08B | $2.96B | $3.41B |
| Other operating costs | $1.81B | $1.10B | $100.0M | — |
| Total operating expenses | $8.93B | $8.60B | $5.69B | $6.24B |
| What was left | ||||
| Operating profit | $3.55B | $3.69B | $4.03B | $4.71B |
| Interest on debt | $652.0M | $711.0M | $668.0M | $667.0M |
| Profit before tax | $3.33B | -$1.64B | $3.17B | -$653.0M |
| Tax | -$216.0M | -$2.0M | $461.0M | -$407.0M |
| Net profit | $3.54B | -$1.65B | $2.69B | -$246.0M |
| EBITDA | $5.65B | $756.0M | $5.02B | $1.20B |
Technicals
Price structure
This stock is in a strong uptrend.
Trend
Strong uptrend
80 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage leans bullish
Tone of tracked coverage
Novavax Highlights Sanofi, Pfizer Catalysts in Matrix-M Platform Pivot
Leans bullishSep 10Incyte at Cantor conference: pipeline advances, post-Jakafi plan By Investing.com
NeutralSep 10Why Did Incannex (NASDAQ:IXHL) Dose Its First Sleep-Apnea Patient?
Leans bullishSep 10Pharvaris’s deucrictibant XR cuts HAE attack rate 83% in Phase III, advancing dual oral strategy
NeutralSep 10VERAXA Biotech Designates Raju Willener as CFO
NeutralSep 9Summit Therapeutics Shares Rise After Upgrade From Jefferies
NeutralSep 9Scinai Immunotherapeutics Ltd. (SCNI) stock price, news, quote and history
NeutralSep 9Tonix Pharmaceuticals Holding Corp. Announces Appointment of Thomas Englese to Chief Commercial Officer, Effective September 8, 2026
NeutralSep 8
Macro
11 macro signals shaping PFE right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results